381 related articles for article (PubMed ID: 25542979)
1. Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis.
Phillips WD; Christadoss P; Losen M; Punga AR; Shigemoto K; Verschuuren J; Vincent A
Exp Neurol; 2015 Aug; 270():29-40. PubMed ID: 25542979
[TBL] [Abstract][Full Text] [Related]
2. Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects.
Viegas S; Jacobson L; Waters P; Cossins J; Jacob S; Leite MI; Webster R; Vincent A
Exp Neurol; 2012 Apr; 234(2):506-12. PubMed ID: 22326541
[TBL] [Abstract][Full Text] [Related]
3. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
Cole RN; Reddel SW; Gervásio OL; Phillips WD
Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
[TBL] [Abstract][Full Text] [Related]
4. Clinical and scientific aspects of muscle-specific tyrosine kinase-related myasthenia gravis.
Reddel SW; Morsch M; Phillips WD
Curr Opin Neurol; 2014 Oct; 27(5):558-65. PubMed ID: 25159928
[TBL] [Abstract][Full Text] [Related]
5. [Pathogenic mechanisms of myasthenia gravis induced by antibodies against muscle-specific kinase].
Maruyama N; Shigemoto K
Rinsho Shinkeigaku; 2007 Nov; 47(11):842-4. PubMed ID: 18210813
[TBL] [Abstract][Full Text] [Related]
6. The mouse passive-transfer model of MuSK myasthenia gravis: disrupted MuSK signaling causes synapse failure.
Ghazanfari N; Trajanovska S; Morsch M; Liang SX; Reddel SW; Phillips WD
Ann N Y Acad Sci; 2018 Jan; 1412(1):54-61. PubMed ID: 29125188
[TBL] [Abstract][Full Text] [Related]
7. Pre- and postsynaptic neuromuscular junction abnormalities in musk myasthenia.
Niks EH; Kuks JB; Wokke JH; Veldman H; Bakker E; Verschuuren JJ; Plomp JJ
Muscle Nerve; 2010 Aug; 42(2):283-8. PubMed ID: 20544919
[TBL] [Abstract][Full Text] [Related]
8. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
[TBL] [Abstract][Full Text] [Related]
9. Muscle specific kinase autoantibodies cause synaptic failure through progressive wastage of postsynaptic acetylcholine receptors.
Morsch M; Reddel SW; Ghazanfari N; Toyka KV; Phillips WD
Exp Neurol; 2012 Oct; 237(2):286-95. PubMed ID: 22789393
[TBL] [Abstract][Full Text] [Related]
10. [Myasthenia gravis induced by autoantibodies against MuSK].
Shigemoto K; Konishi T; Ohta M
Nihon Rinsho; 2008 Jun; 66(6):1149-54. PubMed ID: 18540361
[TBL] [Abstract][Full Text] [Related]
11. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
[TBL] [Abstract][Full Text] [Related]
12. Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis.
Plomp JJ; Huijbers MG; van der Maarel SM; Verschuuren JJ
Ann N Y Acad Sci; 2012 Dec; 1275():114-22. PubMed ID: 23278586
[TBL] [Abstract][Full Text] [Related]
13. Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis.
Huijbers MG; Plomp JJ; van Es IE; Fillié-Grijpma YE; Kamar-Al Majidi S; Ulrichts P; de Haard H; Hofman E; van der Maarel SM; Verschuuren JJ
Exp Neurol; 2019 Jul; 317():133-143. PubMed ID: 30851266
[TBL] [Abstract][Full Text] [Related]
14. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
Hoch W; McConville J; Helms S; Newsom-Davis J; Melms A; Vincent A
Nat Med; 2001 Mar; 7(3):365-8. PubMed ID: 11231638
[TBL] [Abstract][Full Text] [Related]
15. Myasthenia gravis experimentally induced with muscle-specific kinase.
Shigemoto K; Kubo S; Jie C; Hato N; Abe Y; Ueda N; Kobayashi N; Kameda K; Mominoki K; Miyazawa A; Ishigami A; Matsuda S; Maruyama N
Ann N Y Acad Sci; 2008; 1132():93-8. PubMed ID: 18096854
[TBL] [Abstract][Full Text] [Related]
16. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis.
Vincent A; Leite MI
Curr Opin Neurol; 2005 Oct; 18(5):519-25. PubMed ID: 16155434
[TBL] [Abstract][Full Text] [Related]
17. Muscle-Specific Receptor Tyrosine Kinase (MuSK) Myasthenia Gravis.
Hurst RL; Gooch CL
Curr Neurol Neurosci Rep; 2016 Jul; 16(7):61. PubMed ID: 27170368
[TBL] [Abstract][Full Text] [Related]
18. Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis.
Mori S; Kubo S; Akiyoshi T; Yamada S; Miyazaki T; Hotta H; Desaki J; Kishi M; Konishi T; Nishino Y; Miyazawa A; Maruyama N; Shigemoto K
Am J Pathol; 2012 Feb; 180(2):798-810. PubMed ID: 22142810
[TBL] [Abstract][Full Text] [Related]
19. Passive transfer models of myasthenia gravis with muscle-specific kinase antibodies.
Verschuuren JJGM; Plomp JJ; Burden SJ; Zhang W; Fillié-Grijpma YE; Stienstra-van Es IE; Niks EH; Losen M; van der Maarel SM; Huijbers MG
Ann N Y Acad Sci; 2018 Feb; 1413(1):111-118. PubMed ID: 29356029
[TBL] [Abstract][Full Text] [Related]
20. [Autoantibodies detected in acetylcholine receptor antibody-negative myasthenia gravis].
Ohta R; Motomura M
Rinsho Byori; 2014 Mar; 62(3):255-60. PubMed ID: 24800501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
